Navigation Links
Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
Date:8/16/2011

st and most advanced is a NADH oxidase inhibitor program that includes lead candidate ME-143 (formerly NV-143). The second is a mitochondrial inhibitor program that includes lead candidate ME-344 (formerly NV-344). The Company expects to initiate a Phase I clinical trial of intravenous ME-143 by September 2011 and submit an Investigational New Drug application for ME-344 by the first quarter of 2012. For more information, please visit www.marshalledwardsinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
2. Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
3. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
4. Marshall Edwards Announces Private Placement
5. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
6. Marshall Edwards Receives Positive Response From NASDAQ
7. Marshall Edwards to Host Annual Meeting of Stockholders
8. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
9. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
10. Medical Device Consultants, Inc. Welcomes Brian Edwards, Senior Regulatory Staff Consultant
11. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RAPIDS, Mich. , Jan. 15, 2014 As health ... the flu virus, select Meijer pharmacies in Michigan ... strep throat to eligible patients, enabling Meijer pharmacists to administer ... strict protocol set by a physician participating in the study. ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... positive,results from a Phase I trial of R1507, a ... in patients with solid,tumors. IGF-1 is one of the ... pathways, which promote cell growth and cell survival. The,IGF-1R ... role in mediating,the resistance to cytotoxic drugs and EGFR/HER2-targeted ...
... tolerated dose for trodusquemine determined, PLYMOUTH MEETING, ... ) today presented data from its dose-escalating,Phase 1 ... candidate for the treatment of obesity. In the ... clinical doses, and,no serious adverse events were seen ...
Cached Medicine Technology:Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507) 2Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507) 3Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507) 4Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 2Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 3Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 4Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 5
(Date:4/23/2014)... could help doctors predict which patients might suffer potentially ... The program, which assesses brain scans using pattern recognition ... passport control, has been developed by researchers at Imperial ... the Wellcome Trust, which used the software are published ... Stroke affects over 15 million people each year worldwide. ...
(Date:4/23/2014)... the United States, it may come as a surprise that ... food due to lack of money or other financial resources. ... University of Illinois using data from the National Health and ... dealing with hunger are also facing negative health and nutrition ... age 60 faced the threat of hungerthat translates to 4.8 ...
(Date:4/23/2014)... the journal Oncotarget , explored tumour heterogeneity ... their own DNA signatures within the same cancer. ... effective, targeted treatment strategies. , Firstly they confirmed ... either the KRAS or BRAF mutation. Secondly, they ... gene mutation have that specific mutation present uniformly ...
(Date:4/22/2014)... and industry leaders visited the New Jersey Institute ... Joel S. Bloom for the launch of the ... that provides a new model for business innovation ... education assets and investment. U.S. Senator Cory Booker, ... Joe Taylor, New Jersey Lieutenant Governor Kim Guadagno, ...
(Date:4/22/2014)... cancers are small cell lung cancers (SCLC), which ... However, researchers at Virginia Commonwealth University Massey Cancer ... leading to this resistance that may lead to ... mediating B-cell lymphoma 2 (Bcl-2) family proteins, which ... their function, this family of proteins can trigger ...
Breaking Medicine News(10 mins):Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:More Americans in their golden years are going hungry 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2
... MINNEAPOLIS, July 27 ATS Medical, Inc. (Nasdaq: ATSI ... today announced that it will release financial results for the second ... August 3, 2009. The Company will host a conference call ... Time (2:00 p.m. Pacific Time) to discuss its second quarter results ...
... ... ... 2009 -- Silver Creek Systems®, the pioneer and leader in automated Data Mastering, announced ... Management from Forrester Research, Inc., author Rob Karel recognizes the value the company delivers ...
... Midbrook is using ... use in hospitals and other medical facilities that are working to prevent infections. , ... (Vocus) July 27, 2009 -- Midbrook, ... case carts and storage cabinets has begun to use copper alloys as an alternative ...
... ... a large pill. Impact Nutritionals, Inc. launches its first product, S7 Prenatal™ Drink Mix, the ... premise that supplements should taste good and be good for you. To celebrate the launch, ... , ...
... ... in a state of crisis largely due to the failure of highly ... individuals. In his latest article, The Perfect Health Plan: Proven, Safe, Effective, ... occur per year from these FDA approved, properly prescribed, and properly administered ...
... Government health officials from 13 African countries today ... medical laboratories, starting a process that the World Health ... an historic step to strengthen health systems and lead ... of Africa,s laboratories are now accredited, in part because ...
Cached Medicine News:Health News:ATS Medical Announces Second Quarter 2009 Earnings Release Date and Conference Call 2Health News:Leading Independent Analyst Firm States Silver Creek Systems Holds A Virtual Monopoly In Delivering Advanced Product Data Quality Capabilities 2Health News:Midbrook Utilizes Copper in Medical Environments 2Health News:Moms, Registered Dietitian, Develop the First All-In-One Prenatal Vitamin in a Great Tasting Drink Mix 2Health News:Research Scientist Reports On Time-Tested Solution To Current Medical Crisis 2Health News:Research Scientist Reports On Time-Tested Solution To Current Medical Crisis 3Health News:Research Scientist Reports On Time-Tested Solution To Current Medical Crisis 4Health News:Leading health organizations launch new accreditation process for laboratories across Africa 2Health News:Leading health organizations launch new accreditation process for laboratories across Africa 3Health News:Leading health organizations launch new accreditation process for laboratories across Africa 4
... IV and the Penilab V have an exceptionally sensitive ... is similar to the Model 1061 shown below, but ... added later. The Penilab V has a Doppler. ... accessories you'll need to get started. Latex rubber ...
... is designed for vascular labs already ... Its primary use will be ... a cuff with air. Blood ... cuffs - a proximal occluding cuff ...
... With its outstanding optical performance, the ... light used for all types of applications. ... micro-lens technology complies with the highest standards ... provides excellent shadow control within the surgical ...
... The DRE-200 ESU units use dedicated digital ... for processing data. This hardware allows parallel ... processing throughput, measuring tissue impedance 5000 times ... processed digitally, being converted to analog only ...
Medicine Products: